RANK-RANKL-OPG in hemophilic arthropathy: From clinical and imaging diagnosis to histopathology

Journal of Rheumatology

Volumn 39, Issue 8, 2012, Pages 1678-1686

  Melchiorre, Daniela ^a,b   Milia, Anna Franca ^a,b,c   Linari, Silvia ^d   Romano, Eloisa ^a,b   Benelli, Gemma ^c   Manetti, Mirko ^c   Guiducci, Serena ^a,b   Ceccarelli, Claudia ^a,b   Innocenti, Massimo ^c   Carulli, Christian ^c   Civinini, Roberto ^c   Morfini, Massimo ^d   Matucci Cerinic, Marco ^a,b   Ibba Manneschi, Lidia ^c  

^a Division of Rheumatology   (Italy)

^b Transfer and High Education DENOthe   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d AOUC   (Italy)

Author keywords

Hemophilic Arthropathy; RANK RANKL OPG system; Synovium; Ultrasonography

Indexed keywords

ANTIRETROVIRUS AGENT; BLOOD CLOTTING FACTOR 8; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA A; HEMOPHILIC ARTHROPATHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JOINT BIOPSY; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; OSTEOCLAST DIFFERENTIATION FACTOR BLOOD LEVEL; OSTEOPROTEGERIN BLOOD LEVEL; PETTERSSON SCORE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RATING SCALE; SCORING SYSTEM; SYNOVECTOMY; SYNOVIUM; TOTAL KNEE REPLACEMENT; WESTERN BLOTTING; WORLD FEDERATION OF HEMOPHILIA ORTHOPEDIC JOINT SCALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HEMARTHROSIS; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE;

EID: 84864555952     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120370     Document Type: Article

References (34)

1. Jansen NW, Roosendaal G, Lafeber FP. Understanding haemophilic arthropathy: An exploration of current open issues. Br J Haematol 2008;143:632-40.
2. Hoots WK. Pathogenesis of hemophilic arthropathy. Semin Hematol 2006;43 Suppl 1:S18-22. (Pubitemid 43150494)
3. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44. (Pubitemid 47236278)
4. Roosendaal G, van Rinsum AC, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW. Haemophilic arthropathy resembles degenerative rather than inflammatory joint disease. Histopathology 1999;34:144-53. (Pubitemid 29083216)
5. Achayra SS, Kaplan RN, Macdonald D, Fabiyi OT, DiMichele D, Lyden D. Neo-angiogenesis contributes to the development of hemophilic synovitis. Blood 2011;117:2484-94.
6. Valentino LA. Blood induced joint disease: The pathophysiology of haemophilic arthropathy. J Thromb Haemost 2010;8:1895-902.
7. Berntorp E, Astermark J, Bjorkman S, Blanchette VS, Fischer K, Giangrande PL, et al. Consensus perspectives on prophylactic therapy for haemophilia: Summary statement. Haemophilia 2003;9 Suppl 1:1-4. (Pubitemid 36622042)
8. Hoots WK, Rodriguez N, Boggio L, Valentino LA. Pathogenesis of haemophilic synovitis: Clinical aspects. Haemophilia 2007;13 Suppl 3:4-9. (Pubitemid 47381206)
9. Baud'huin M, Duplomb L, Téletchéa S, Charrier C, Maillasson M, Fouassier M, et al. Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival. J Biol Chem 2009;284:31704-13.
10. Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D. The abundant synovial expression of the RANK/RANKL/osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum 2008;58:718-29. (Pubitemid 351364869)
11. Saidenberg-Kermanac'h N, Cohen-Solal M, Bessis N, De Vernejoul MC, Boissier MC. Role of osteoprotegerin in rheumatoid inflammation. Joint Bone Spine 2004;71:9-13.
12. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76. (Pubitemid 28180851)
13. Holstead Jones D, Kong Y-Y, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 2002;61 Suppl II:ii32-9. (Pubitemid 35221710)
14. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-53. (Pubitemid 32646379)
15. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19. (Pubitemid 27199902)
16. Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005;204:714-23. (Pubitemid 40934668)
17. Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 2005;26:63-9. (Pubitemid 41531517)
18. Katsarou O, Terpos E, Chatzismalis P, Provelengios S, Adraktas T, Hadjidakis D, et al. Increased bone resorption is implicated in the pathogenesis of bone loss in hemophiliacs: Correlations with haemophilic arthropathy and HIV infection. Ann Hematol 2010;89:67-74.
19. Christoforidis A, Economou M, Papadopoulou E, Kazantzidou E, Farmaki E, Tzimouli V, et al. Comparative study of dual energy X-ray absorptiometry and quantitative ultrasonography with the use of biochemical markers of bone turnover in boys with haemophilia. Haemophilia 2011;17:e217-22.
20. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population. Where do we stand? Haemophilia 2004;10:97-104. (Pubitemid 40045427)
21. Gilbert MS. Prophylaxis: Musculoskeletal evaluation. Semin Hematol 1993;3 Suppl 2:3-6. (Pubitemid 23212308)
22. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of the haemophilic arthropathy. Clin Orthop Relat Res 1980;149:153-9.
23. Melchiorre D, Linari S, Innocenti M, Biscoglio I, Toigo M, Cerinic MM, et al. Ultrasound detects joint damage and bleeding in haemophilic arthropathy: A proposal of a score. Haemophilia 2011;17:112-7.
24. Jansen NW, Roosendaal G, Bijlsma JW, Degroot J, Lafeber FP. Exposure of human cartilage tissue to low concentrations of blood for a short period of time leads to prolonged cartilage damage. An in vitro study. Arthritis Rheum 2007;56:199-207. (Pubitemid 46106192)
25. Roosendaal G, Vianen ME, Marx JJ, van den Berg HM, Lafeber FP, Bijlsma JW. Blood-induced joint damage: A human in vitro study. Arthritis Rheum 1999;42:1025-32. (Pubitemid 29215015)
26. Roosendaal G, Vianen ME, Wenting MJ, van Rinsum AC, van den Berg HM, Lafeber FP, et al. Iron deposit and catabolic properties of synovial tissue from patients with haemophilia. J Bone Joint Surg Br 1998;80:540-5.
27. Roosendaal G, Jansen NW, Schutgens R, Lafeber FP. Haemophilic arthropathy: The importance of the earliest haemarthroses and consequences for treatment. Haemophilia 2008;14 Suppl 6:4-10.
28. Acharya S, Schloss R, Dyke JP, Mintz DN, Christos P, DiMichele DM, et al. Power Doppler sonography in the diagnosis of hemophilic synovitis - A promising tool. J Thromb Haemost 2008;6:2055-61.
29. Abshire T. Unraveling hemophilic arthropathy. Blood 2011;117:2302-3.
30. Khawaji M, Akesson K, Berntorp E. Long-tem prophylaxis in severe haemophilia seems to preserve bone mineral density. Haemophilia 2009;15:261-6.
31. Haynes DR, Barg E, Crotti TN, Holding C, Weedon H, Atkins GJ, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology 2003;42:123-34. (Pubitemid 36131578)
32. Vega D, Maalouf NM, Sakhaee K. The role of receptor activator of nuclear factor-kB (RANK)/RANK ligand/osteoprotegerin: Clinical implications. J Clin Endocrinol Metab 2007;92:4514-21. (Pubitemid 350223419)
33. Pulsatelli L, Dolzani P, Silvestri T, Caraceni P, Facchini A, Ravaglia G, et al. Soluble receptor activator of nuclear factor-kB ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases. Biogerontology 2004;5:119-27. (Pubitemid 39137528)
34. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor-kb ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor treatment. Arthritis Rheum 2002;46:1744-53. (Pubitemid 34774505)